prophase financials, page-31

Hi Dougal, my interpretation waa that cash flow positive was determined by the success of Cellucreme and what they do with oxypatch. I posted prior to that lodge info that I beleived PoH could be cash flow positive in approx 12 months depeding on success of cellucreme and oxypatch development costs. I suggested that oxypatch would be delayed to save money while cellucreme gains traction to self fund. There has been only been mention of starting phase 2 trials recently. Thus matching my thoughts that phase 3 will wait till we have cash.

Also remember PoH did a cellucreme trial in nsw started in Nov. We havent had that result told to us but I have bet more poh shares that it was successful and led to those statements. They knew how well
it worked prior to this funding arrangement and the US trials we are waiting for and maybe a major partner too.